Clinical and haemodynamic outcomes in 658 patients receiving the Perceval sutureless aortic valve: early results from a prospective European multicentre study (the Cavalier Trial)
Key result
Implantation of the Perceval sutureless aortic valve was successful in 95.4% of patients, with a 30-day overall mortality rate of 3.7% and improved haemodynamic gradients.
Population
658 consecutive patients undergoing aortic valve replacement, mean age 77.8 years, 64.4% female, mean…
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Early safety appears acceptable in this cohort; leaves open need for RCTs versus conventional AVR.
Study Design
Type
Cohort (n=658)
Multicenter
Yes
Structured PICO
P
Population
658 patients (mean age 77.8 years, 64.4% female) undergoing aortic valve replacement, excluding those with congenital bicuspid valves, followed for 30 days.
E
Exposure
Perceval sutureless aortic valve implantation
O
Outcome
30-day clinical and haemodynamic outcomes (safety and performance)safety
The Perceval sutureless aortic valve demonstrates favorable early safety and hemodynamic profiles at 30 days, offering a viable alternative to traditional biological AVR, particularly in older patients.
Cite This Study
Laborde et al. (2015) conducted a cohort in Aortic valve replacement (n=658). Perceval sutureless aortic valve was evaluated on 30-day overall mortality. Implantation of the Perceval sutureless aortic valve was successful in 95.4% of patients, with a 30-day overall mortality rate of 3.7% and improved haemodynamic gradients.